Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground

 
• By Alaric DeArment
  
Quince Therapeutics said the Phase III NEAT trial of eDSP did not meet its primary or key secondary endpoints. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cell Therapies

More from Advanced Therapies